Zanidatamab-hrii India Price & Patient Access Guide
Zanidatamab (Ziihera) 300 mg Injection available in India A diagnosis of HER2-positive biliary tract cancer can present significant treatment challenges, particularly when the disease has progressed despite previous therapy. For eligible patients, advances in targeted cancer treatment have created new options that focus on specific molecular characteristics of the tumor rather than relying solely on conventional treatment approaches. Zanidatamab-hrii is a HER2-directed bispecific antibody developed to target HER2-positive cancer cells through a dual-binding mechanism. Unlike therapies that interact with a single target site, Zanidatamab binds to two distinct extracellular domains of the HER2 receptor. This dual engagement promotes receptor internalization and reduces HER2 expression on the tumor cell surface. In addition, Zanidatamab activates multiple immune-mediated pathways involved in cancer cell elimination, including complement-dependent cytotoxicity (CDC), antibody-depend...
